CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of disease-driving genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the 2017 BIO CEO & Investor Conference. Details are as follows:
2017 BIO CEO & Investor Conference
Date: Tuesday, February 14
Time: 9:30-9:55 a.m. ET
Location: The Waldorf Astoria, 301 Park Avenue, New York, NY
A live webcast of the presentation will be available on the News & Investors section of the Syros website at www.syros.com. An archived replay will be available for approximately 30 days following the presentation.
About Syros Pharmaceuticals
Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros’ gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and immune-mediated diseases and is advancing a growing pipeline of gene control medicines. Syros’ lead drug candidates are SY-1425, a selective RAR agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor with potential in a range of solid tumors and blood cancers. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170207005416/en/
Naomi Aoki, 617-283-4298
Stern Investor Relations, Inc.
Hannah Deresiewicz, 212-362-1200
Source: Syros Pharmaceuticals
Released February 7, 2017